2021
The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals
Mistler CB, Curley CM, Rosen AO, El-Krab R, Wickersham JA, Copenhaver MM, Khati A, Shrestha R. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals. Journal Of Community Health 2021, 46: 960-966. PMID: 33770334, PMCID: PMC7996112, DOI: 10.1007/s10900-021-00979-0.Peer-Reviewed Original ResearchConceptsOpioid use disorderHIV prevention servicesSTI testingHIV counselorsPrEP prescriptionPrevention servicesCOVID-19Pre-exposure prophylaxis servicesOpioid use disorder treatmentCOVID-19 pandemicClean injection equipmentOpioid-dependent individualsOpioid-dependent peopleUse disorder treatmentInjection equipmentHIV testingInfection testingBlood testingHIV preventionUse disordersPWIDDisorder treatmentDoctor's appointmentAdverse effectsCase managers
2017
Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, Copenhaver M. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS And Behavior 2017, 22: 1228-1238. PMID: 28695388, PMCID: PMC5762432, DOI: 10.1007/s10461-017-1851-1.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSex-related risk behaviorsHigh-risk drug usersAcceptability of PrEPHigh-risk PWUDPrimary HIV preventionHIV prevention approachesDrug treatment settingsKey risk populationsHIV-negative PWUDHigh acceptabilityHIV clinicPrEP acceptabilityHIV testingPrEP uptakeMethadone clinicsHIV preventionRisk populationsSide effectsTreatment settingsDrug usersPrEP attributesRisk behaviorsPrEPUnderserved populationsInterest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program
Shrestha R, Karki P, Copenhaver M. Interest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program. AIDS Care 2017, 29: 1144-1148. PMID: 28478706, PMCID: PMC6081193, DOI: 10.1080/09540121.2017.1325439.Peer-Reviewed Original ResearchConceptsHigh-risk PWUDMethadone maintenance programHIV preventionMedication remindersHIV risk reduction informationRisk behaviorsSex-related risk behaviorsHigh-risk drug usersMHealth technologiesHIV prevention toolHIV risk reductionHIV prevention approachesHIV risk behaviorsDrug treatment settingsRisk Behavior AssessmentHIV prevention effortsHIV-negative PWUDUse of mHealthNew intervention strategiesDepressive symptomsTreatment settingsDrug usersHealthcare providersMultivariate analysisPrevention effortsIntent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis
Shrestha R, Karki P, Huedo-Medina TB, Copenhaver M. Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis. Journal Of The Association Of Nurses In AIDS Care 2017, 28: 612-621. PMID: 28478870, PMCID: PMC7451137, DOI: 10.1016/j.jana.2017.04.005.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsNeurocognitive impairmentRisk behaviorsPreexposure prophylaxisSelf-reported neurocognitive symptomsHigh-risk drug usersHigh-risk PWUDPrEP uptakeNeurocognitive symptomsHIV riskDrug usersSimilar outcomesUnderserved populationsSignificant correlatesProphylaxisImportant unanswered questionsPreliminary evidencePrEPDissemination effortsMediation analysisUnanswered questionsVariables of interestHIVSymptomsClinicians
2016
Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment
Shrestha R, Huedo-Medina TB, Altice FL, Krishnan A, Copenhaver M. Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. AIDS And Behavior 2016, 21: 3100-3110. PMID: 28025735, PMCID: PMC5484759, DOI: 10.1007/s10461-016-1637-x.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultCell PhoneConnecticutDelivery of Health CareDrug UsersFemaleHIV InfectionsHumansInternetMaleMethadoneNeurocognitive DisordersOpiate Substitution TreatmentPatient Acceptance of Health CarePrevalenceRisk FactorsRisk-TakingSexual BehaviorSmartphoneSubstance Abuse, IntravenousTelemedicineText MessagingConceptsSex-related risk behaviorsNeurocognitive impairmentDrug usersRisk behaviorsHIV-negative drug usersHigh-risk drug usersHigh-risk populationHigh-risk peopleHIV prevention effortsUse of mHealthMethadone clinicsHIV preventionHigh prevalenceMedication remindersHealth programsMHealth acceptancePrevention effortsHealth conditionsMHealth technologiesConvenience sampleDrugsStandardized assessmentReal-world acceptanceMobile healthPhone callsWillingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment
Shrestha R, Altice FL, Huedo-Medina TB, Karki P, Copenhaver M. Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. AIDS And Behavior 2016, 21: 1299-1308. PMID: 27990587, PMCID: PMC5380590, DOI: 10.1007/s10461-016-1650-0.Peer-Reviewed Original ResearchConceptsHigh-risk PWUDBehavioral skills modelCommunity-based methadone maintenance treatmentPre-exposure prophylaxis trialsSex-related HIV risk behaviorsHigh-risk drug usersPre-exposure prophylaxisIMB modelMethadone maintenance treatmentEfficacy of PrEPUse of PrEPHIV risk behaviorsKey risk populationsHealth behavior changeHIV acquisitionProphylaxis trialsHIV infectionMaintenance treatmentHIV preventionRisk populationsDrug usersRisk behaviorsPrEPPWUDIntervention developmentTreatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment
Shrestha R, Karki P, Huedo-Medina TB, Copenhaver M. Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment. Journal Of The Association Of Nurses In AIDS Care 2016, 28: 85-94. PMID: 27769735, PMCID: PMC5183513, DOI: 10.1016/j.jana.2016.09.007.Peer-Reviewed Original ResearchModeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment
Huedo-Medina TB, Shrestha R, Copenhaver M. Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment. AIDS And Behavior 2016, 20: 1646-1657. PMID: 27052845, PMCID: PMC4945437, DOI: 10.1007/s10461-016-1394-x.Peer-Reviewed Original ResearchConceptsNeurocognitive impairmentCommunity-based methadone maintenance treatmentHIV risk reduction informationSex-related HIV risk behaviorsHIV risk reduction behaviorsHigh-risk PWUDHIV prevention benefitsMethadone maintenance treatmentHIV prevention outcomesOpioid-dependent individualsSignificant neurocognitive impairmentHIV risk behaviorsHIV prevention behaviorsRisk reduction informationHealth behavior changeBehavioral skills modelRisk reduction behaviorsRisk reduction outcomesMaintenance treatmentEfficacious interventionsDrug usersPrevention benefitsPrevention outcomesPrevention behaviorsRisk behaviors